Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
Protagonist Therapeutics (NASDAQ: PTGX) has announced that its CEO, Dinesh V. Patel, Ph.D., will engage in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 11 a.m. EDT. The event will be available via live and archived webcast on the company's investor website. Protagonist Therapeutics focuses on developing novel peptide-based therapeutics, with three clinical-stage assets: PTG-300 for blood disorders, PTG-200 for inflammatory bowel disease, and PN-943 also targeting inflammatory bowel disease.
- None.
- None.
NEWARK, Calif., Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference.
Presentation details:
Event: H.C. Wainwright 22nd Annual Global Investment Conference
Date: Monday, September 14, 2020
Time: 11 a.m. EDT
A live and archived webcast of the fireside chat can be accessed by visiting the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-hc-wainwright-22nd-annual-global-investment-conference-301127980.html
SOURCE Protagonist Therapeutics, Inc.
FAQ
When is Protagonist Therapeutics participating in the H.C. Wainwright Conference?
Who is representing Protagonist Therapeutics at the conference?
What time is the Protagonist Therapeutics fireside chat at the conference?
How can I access the Protagonist Therapeutics conference presentation?
What are the main therapeutic areas Protagonist Therapeutics is focusing on?
